Overview of implantable cardiac defibrillators for primary prevention of sudden cardiac death in high risk patients: clinical efficacy, cost-effectiveness, and psychosocial issues.

Ho C, Li H, Noorani H, Cimon K, Campbell K, Tang A, Birnie D
Record ID 32007000128
English
Authors' objectives:

This overview examines the use of implantable cardiac defibrillators for primary prevention of sudden cardiac death in high risk patients.

Authors' recommendations: Implications for Decision Making : ICDs, with optimal pharmacologic therapy, significantly reduce SCD and all-cause death in patients at high risk. : ICDs are effective in reducing SCD in patients with ischemic and non-ischemic heart disease. : ICD therapy is expensive but some reviewed studies showed that ICDs are cost-effective if the willingness to pay is 50,000 USD per quality adjusted life year (QALY). More study with a broader target population is warranted. : Poor psychosocial outcomes in ICD patients may occur as a result of their underlying cardiac condition, rather than as a direct response to ICDs. : ICD therapy r primary prevention of SCD would result in a substantial budget impact. There are also infrastructure issues that would need to be addressed in order to meet demand.
Authors' methods: Overview
Details
Project Status: Completed
URL for project: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/696
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Defibrillators, Implantable
  • Death, Sudden, Cardiac
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.